C. Pisano

Real-World Outcomes of Second-Line Pembrolizumab in Urothelial Carcinoma: A Multicenter Analysis from the Campania Oncological Network (ROC)

Rosa Tambaro, Gabriele Calvanese, Andrea Muto, L. Formisano et autres

it (code pays fourni par la source)

Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study

Rebecca Kristeleit, S. Ghamande, Alla Lisyanskaya, A. Oaknin et autres

BACKGROUND: We report the long-term efficacy and safety from the multicenter, randomized, double-blind, placebo-controlled, phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 (NCT03522246) study of first-line rucaparib maintenance for advanced ovarian cancer. PATIENTS AND METHODS: Patients were randomized 4 : 1 to oral rucaparib + intravenous (i.v.) …

gb, us, ru, es, kr, au, it, ca, gr, tw, tr, pl, il, cz, jp (code pays fourni par la source)

28P Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study

V. Tuninetti, Elisa Virano, V. Salutari, A. Ricotti et autres

Cemiplimab is an immunoglobulin G4 monoclonal antibody targeting the programmed cell death-1 receptor. A nominal use program is available in Italy for advanced cervical cancer (CC) patients treated with platinum-based chemotherapy based on the results of the EMPOWER-Cervical 1/GOG-3016/ENGOTcx9 trial. This real-world, …

it (code pays fourni par la source)

45P MITO39: Effiacy and tolerability of PLD-trabectedin in the treatment of relapsed ovarian cancer after maintenance therapy with PARP-i, a MITO observational case-control study

M. Turinetto, S. Pignata, C. Pisano, C. Zamagni et autres

PLD-Trabectedin is currently an option for patients diagnosed with relapsed ovarian cancer (ROC) with a platinum free interval (PFI) of at least 6 months; also, the advent of PARP-i maintenance therapy has revolutionalized the landscape, creating an ever-growing population who progress afterwards …

it, ca, my (code pays fourni par la source)